gatifloxacin has been researched along with Pneumococcal Infections in 26 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Pneumococcal Infections: Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare gatifloxacin with amoxicillin/clavulanate in children with recurrent or nonresponsive acute otitis media (AOM)." | 9.11 | Randomized, investigator-blinded, multicenter study of gatifloxacin versus amoxicillin/clavulanate treatment of recurrent and nonresponsive otitis media in children. ( Arguedas, A; Echols, R; Hamed, KA; Pierce, P; Rodriguez, A; Sáez-Llorens, X; Yang, J, 2005) |
| "To compare the clinical efficacy of gatifloxacin with amoxicillin/clavulanate for the treatment of acute otitis media treatment failure and recurrent otitis media." | 9.11 | Randomized, investigator-blinded, multicenter, comparative study of gatifloxacin versus amoxicillin/clavulanate in recurrent otitis media and acute otitis media treatment failure in children. ( Arguedas, A; Biswas, D; Echols, R; Hamed, KA; Husseman, M; Pichichero, M; Pierce, P; Sher, L, 2005) |
| "Besifloxacin is as effective as moxifloxacin and gatifloxacin in a rabbit model for topical prophylaxis and treatment of PRSP-induced endophthalmitis." | 7.76 | Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis. ( Hesje, CK; Marquart, ME; Moore, Q; Norcross, EW; Sanders, ME; Sanfilippo, CM; Shafiee, A, 2010) |
| "To compare gatifloxacin with amoxicillin/clavulanate in children with recurrent or nonresponsive acute otitis media (AOM)." | 5.11 | Randomized, investigator-blinded, multicenter study of gatifloxacin versus amoxicillin/clavulanate treatment of recurrent and nonresponsive otitis media in children. ( Arguedas, A; Echols, R; Hamed, KA; Pierce, P; Rodriguez, A; Sáez-Llorens, X; Yang, J, 2005) |
| "To compare the clinical efficacy of gatifloxacin with amoxicillin/clavulanate for the treatment of acute otitis media treatment failure and recurrent otitis media." | 5.11 | Randomized, investigator-blinded, multicenter, comparative study of gatifloxacin versus amoxicillin/clavulanate in recurrent otitis media and acute otitis media treatment failure in children. ( Arguedas, A; Biswas, D; Echols, R; Hamed, KA; Husseman, M; Pichichero, M; Pierce, P; Sher, L, 2005) |
| "Besifloxacin is as effective as moxifloxacin and gatifloxacin in a rabbit model for topical prophylaxis and treatment of PRSP-induced endophthalmitis." | 3.76 | Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis. ( Hesje, CK; Marquart, ME; Moore, Q; Norcross, EW; Sanders, ME; Sanfilippo, CM; Shafiee, A, 2010) |
| "Gatifloxacin was more potent than levofloxacin, but both presented equivalent efficacy." | 1.37 | Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae. ( Dalla Costa, T; de Andrade, C; Tasso, L, 2011) |
| "Ciprofloxacin resistance was greatest in people >64 years of age and least in those <16 years of age." | 1.34 | Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. ( Adam, HJ; Baudry, TJ; Hoban, CJ; Hoban, DJ; Laing, NM; Nichol, KA; Schurek, KN; Zhanel, GG, 2007) |
| " Previously described population pharmacokinetic models of gatifloxacin and levofloxacin administration in patients with serious CAP were utilised to simulate gatifloxacin and levofloxacin pharmacokinetics." | 1.33 | Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. ( Hoban, DJ; Noreddin, AM; Zhanel, GG, 2005) |
| "First, a previously derived population pharmacokinetic model, with patient demographics, was used to estimate gatifloxacin AUC0-24 following a dosage regimen of 400 mg/24 h in 10 index patients with severe hyperglycaemia." | 1.32 | Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. ( Ambrose, PG; Bhavnani, SM; Cirincione, BB; Grasela, TH; Piedmonte, M, 2003) |
| "The fibrin clots were suspended into the models and removed, in triplicate, at various time points over 48 h." | 1.31 | Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model. ( Hershberger, E; Rybak, MJ, 2000) |
| "Gatifloxacin has a higher probability of achieving target AUC:MIC ratios than levofloxacin." | 1.31 | The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. ( Ambrose, PG; Grasela, DM, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 21 (80.77) | 29.6817 |
| 2010's | 4 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kosowska-Shick, K | 1 |
| Credito, KL | 1 |
| Pankuch, GA | 1 |
| DeWasse, B | 1 |
| McGhee, P | 1 |
| Appelbaum, PC | 1 |
| Rozen, DE | 1 |
| McGee, L | 1 |
| Levin, BR | 1 |
| Klugman, KP | 1 |
| LaPlante, KL | 1 |
| Rybak, MJ | 2 |
| Tsuji, B | 1 |
| Lodise, TP | 1 |
| Kaatz, GW | 1 |
| Xu, X | 1 |
| Cai, L | 1 |
| Xiao, M | 1 |
| Kong, F | 1 |
| Oftadeh, S | 1 |
| Zhou, F | 1 |
| Gilbert, GL | 1 |
| Norcross, EW | 1 |
| Sanders, ME | 1 |
| Moore, Q | 1 |
| Sanfilippo, CM | 1 |
| Hesje, CK | 1 |
| Shafiee, A | 1 |
| Marquart, ME | 1 |
| Patel, SN | 1 |
| McGeer, A | 1 |
| Melano, R | 1 |
| Tyrrell, GJ | 1 |
| Green, K | 1 |
| Pillai, DR | 1 |
| Low, DE | 1 |
| Tasso, L | 1 |
| de Andrade, C | 1 |
| Dalla Costa, T | 1 |
| Bello, S | 1 |
| Torres, A | 1 |
| Ambrose, PG | 3 |
| Bhavnani, SM | 2 |
| Cirincione, BB | 1 |
| Piedmonte, M | 2 |
| Grasela, TH | 1 |
| Garrison, MW | 1 |
| Schimmels, JA | 1 |
| Madaras-Kelly, KJ | 1 |
| Dagan, R | 1 |
| Arguedas, A | 3 |
| Schaad, UB | 1 |
| Anon, JB | 1 |
| Owen, JS | 1 |
| Van Wart, S | 1 |
| McPhee, ME | 1 |
| Jones, RN | 2 |
| Jorgensen, JH | 1 |
| Crawford, SA | 1 |
| McElmeel, LM | 1 |
| Whitney, CG | 1 |
| Sáez-Llorens, X | 1 |
| Rodriguez, A | 1 |
| Hamed, KA | 2 |
| Yang, J | 1 |
| Pierce, P | 2 |
| Echols, R | 2 |
| Sher, L | 1 |
| Husseman, M | 1 |
| Pichichero, M | 1 |
| Biswas, D | 1 |
| Noreddin, AM | 1 |
| Hoban, DJ | 2 |
| Zhanel, GG | 3 |
| Donnenfeld, RS | 1 |
| Perry, HD | 1 |
| Solomon, R | 1 |
| Jensen, HG | 1 |
| Stein, J | 1 |
| Snyder, RW | 1 |
| Wittpenn, JR | 1 |
| Donnenfeld, ED | 1 |
| Adam, HJ | 1 |
| Schurek, KN | 1 |
| Nichol, KA | 1 |
| Hoban, CJ | 1 |
| Baudry, TJ | 1 |
| Laing, NM | 1 |
| Kays, MB | 1 |
| Reimann, MA | 1 |
| Jacobi, J | 1 |
| Denys, GA | 1 |
| Smith, DW | 1 |
| Wack, MF | 1 |
| Dobay, O | 1 |
| Rozgonyi, F | 1 |
| Ghidán, A | 1 |
| Matuz, M | 1 |
| Nagy, K | 1 |
| Amyes, SG | 1 |
| Tomizawa, H | 1 |
| Tateda, K | 1 |
| Miyazaki, S | 1 |
| Yamaguchi, K | 1 |
| Hershberger, E | 1 |
| Grasela, DM | 1 |
| Nicodemo, AC | 1 |
| Mendes, CM | 1 |
| Oplustil, CP | 1 |
| Sinto, S | 1 |
| White, RL | 1 |
| Enzweiler, KA | 1 |
| Friedrich, LV | 1 |
| Wagner, D | 1 |
| Hoban, D | 1 |
| Bosso, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label Noncomparative, Multicenter, Clinical Trail Measuring Time Related Clinical Response Factors in Relation to Time to Bacterial Eradication With Tigecycline Treatment in Patients With Catheter Infection[NCT00419991] | Phase 4 | 10 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for gatifloxacin and Pneumococcal Infections
| Article | Year |
|---|---|
Potential role of fluoroquinolone therapy in childhood otitis media.
Topics: Anti-Infective Agents; Child; Child, Preschool; Drug Resistance, Microbial; Fluoroquinolones; Gatifl | 2004 |
3 trials available for gatifloxacin and Pneumococcal Infections
| Article | Year |
|---|---|
Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis.
Topics: Acute Disease; Anti-Bacterial Agents; Coagulase; Enterobacter aerogenes; Enterobacteriaceae Infectio | 2004 |
Randomized, investigator-blinded, multicenter study of gatifloxacin versus amoxicillin/clavulanate treatment of recurrent and nonresponsive otitis media in children.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Child; Child, Preschool; Femal | 2005 |
Randomized, investigator-blinded, multicenter, comparative study of gatifloxacin versus amoxicillin/clavulanate in recurrent otitis media and acute otitis media treatment failure in children.
Topics: Acute Disease; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Child; Child, P | 2005 |
22 other studies available for gatifloxacin and Pneumococcal Infections
| Article | Year |
|---|---|
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
Topics: Amidohydrolases; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Peptides; Pneumococcal Inf | 2007 |
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
Topics: DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Se | 2007 |
Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
Topics: Area Under Curve; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemiflo | 2007 |
Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Child, Preschool; DNA Transposable Elements; Drug Resista | 2010 |
Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Micr | 2010 |
Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
Topics: Anti-Bacterial Agents; Aza Compounds; Binding Sites; Canada; Ciprofloxacin; DNA Gyrase; DNA Topoisom | 2011 |
Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Area Under Curve; Culture Media; Fluoroquinolones; Gatifloxacin; Humans; Levo | 2011 |
[Pneumococcus and quinolone resistance].
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child, Preschool; Ciproflo | 2003 |
Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction.
Topics: Aged; Aged, 80 and over; Aging; Algorithms; Anti-Bacterial Agents; Area Under Curve; Bayes Theorem; | 2003 |
In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
Topics: Analysis of Variance; Aza Compounds; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistanc | 2003 |
Detection of resistance to gatifloxacin and moxifloxacin in Streptococcus pneumoniae with the VITEK 2 instrument.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Hu | 2004 |
Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
Topics: Adult; Aged; Community-Acquired Infections; Drug Administration Schedule; Epidemiologic Methods; Flu | 2005 |
A comparison of gatifloxacin to ciprofloxacin in the prophylaxis of Streptococcus pneumoniae in rabbits in a LASIK model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Cornea; Disease Models, Animal; Eye Infections, Bacte | 2006 |
Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aza Compounds; Bacterial Proteins; Canada; | 2007 |
Selection of a gyrA mutation and treatment failure with gatifloxacin in a patient with Streptococcus pneumoniae with a preexisting parC mutation.
Topics: Aged, 80 and over; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance; Female; Fluoroquinolones; Gati | 2007 |
The first steps towards fluoroquinolone resistance in Hungarian pneumococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Carbonyl Cyanide m-Chlorophenyl Hydrazone; | 2006 |
Antibacterial activity of AM-1155 against penicillin-resistant Streptococcus pneumoniae.
Topics: Animals; Anti-Infective Agents; Fluoroquinolones; Gatifloxacin; Male; Mice; Mice, Inbred CBA; Microb | 1998 |
Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Topics: Anti-Infective Agents; Blood Coagulation; Ciprofloxacin; Fibrin; Fluoroquinolones; Gatifloxacin; Hum | 2000 |
The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Area Under Curve; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Micro | 2000 |
Conventional dogma applied to quinolones? Time for a change.
Topics: 4-Quinolones; Anti-Infective Agents; Aza Compounds; Clinical Trials as Topic; Fluoroquinolones; Gati | 2001 |
In vitro activity of fluoroquinolones (gatifloxacin, levofloxacin and trovafloxacin) and seven other antibiotics against Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Microbial; Drug Resistance, Multiple; | 2001 |
Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ceftriaxone; Ch | 2002 |